• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MacroGenics Inc.

    4/11/25 4:01:29 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MGNX alert in real time by email
    DEFA14A 1 defa14a2025.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.     )
    Filed by the Registrant  ☒                             Filed by a Party other than the Registrant   ☐
    Check the appropriate box:
     
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material under § 240.14a-12

    MACROGENICS, INC.
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):
    ☒No fee required.
    ☐Fee paid previously with preliminary materials.
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11




    mgnx_naax310xpagex1a.jpg



    mgnx_naax310xpagex2a.jpg

    Get the next $MGNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGNX

    DatePrice TargetRatingAnalyst
    11/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/1/2024Buy → Neutral
    BTIG Research
    7/31/2024$18.00 → $5.00Buy → Neutral
    B. Riley Securities
    7/31/2024Buy → Neutral
    Guggenheim
    5/10/2024$24.00 → $8.00Outperform → Market Perform
    BMO Capital Markets
    5/10/2024$29.00 → $7.00Buy → Hold
    Stifel
    5/10/2024Buy → Hold
    TD Cowen
    4/26/2024$25.00Buy
    B. Riley Securities
    More analyst ratings

    $MGNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MARGENZA

    Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

    12/20/20 4:31:01 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sr VP, Technical Ops Spitznagel Thomas

    4 - MACROGENICS INC (0001125345) (Issuer)

    8/19/25 4:15:05 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Senior VP and General Counsel Peters Jeffrey Stuart

    4 - MACROGENICS INC (0001125345) (Issuer)

    8/19/25 4:12:13 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Koenig Scott converted options into 52,829 shares, increasing direct ownership by 7% to 830,244 units (SEC Form 4)

    4 - MACROGENICS INC (0001125345) (Issuer)

    8/15/25 5:05:12 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

    Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ® Cash, cash equivalents and marketable securities of $176.5 million as of June 30, 2025; cash runway through first half of 2027 ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress. "Over the past s

    8/14/25 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Appoints Eric Risser as President and Chief Executive Officer

    ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company's corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as Presi

    8/13/25 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

    MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics' cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard in exchange for a capped royalty interest on future global net sales of ZYNYZ (retifanlimab-dlwr). ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte pursuant

    6/10/25 7:00:00 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Biotech Target N V bought $669,585 worth of shares (150,000 units at $4.46), increasing direct ownership by 2% to 9,929,963 units (SEC Form 4)

    4 - MACROGENICS INC (0001125345) (Issuer)

    10/4/23 3:31:17 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    SEC Filings

    View All

    SEC Form S-8 filed by MacroGenics Inc.

    S-8 - MACROGENICS INC (0001125345) (Filer)

    8/14/25 4:09:14 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by MacroGenics Inc.

    10-Q - MACROGENICS INC (0001125345) (Filer)

    8/14/25 4:06:06 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MACROGENICS INC (0001125345) (Filer)

    8/14/25 4:04:17 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MacroGenics downgraded by JMP Securities

    JMP Securities downgraded MacroGenics from Mkt Outperform to Mkt Perform

    11/7/24 6:29:13 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics downgraded by BTIG Research

    BTIG Research downgraded MacroGenics from Buy to Neutral

    8/1/24 6:28:50 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded MacroGenics from Buy to Neutral and set a new price target of $5.00 from $18.00 previously

    7/31/24 6:30:32 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    Financials

    Live finance-specific insights

    View All

    MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

    First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for

    5/13/25 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Announces Date of First Quarter 2025 Financial Results

    ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future. About MacroGenics, Inc.MacroGenics (the Company) is a biopharm

    5/6/25 4:30:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

    Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical com

    3/20/25 4:02:38 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    Leadership Updates

    Live Leadership Updates

    View All

    MacroGenics Appoints Eric Risser as President and Chief Executive Officer

    ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company's corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as Presi

    8/13/25 4:01:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Announces Leadership Transition

    Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the t

    10/30/24 7:30:00 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

    ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu will serve as a member of MacroGenics' Science and Technology Committee and Ms. Karson will serve as a member of the Company's Audit Committee. Following the appointment of Dr. Liu and Ms. Karson, MacroGenics' Board will comprise ten directors, nine of whom are independent. "We are delighted to have both Margaret and Meenu join Ma

    1/4/23 4:30:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

    SC 13G/A - MACROGENICS INC (0001125345) (Subject)

    11/14/24 5:13:06 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    6/4/24 4:53:11 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care